Ivy Center Seminar Series
The Ivy Center Seminar Series is an opportunity for world-class scientists and investigators to share recent progress with the Ivy Center’s multidisciplinary team in an informal format. Seminars are held on Mondays 8:30-9:30am and include ample time for discussion and candid interaction. Topics are wide-ranging, from basic science to clinical research, but always focus on new translational science horizons in brain cancer biology and treatment. Due to the inclusion of unpublished and/or confidential data, Ivy Center seminars are only available to members of the Ivy Center community.
Upcoming Seminars
To be announced
Past Seminars
August 21, 2023
“Precision Medicine in the Clinic: Discovery in Real Time””
Razelle Kurzrock, MD
Professor of Medicine, Associate Director, Clinical Research
Linda T. and John A. Mellowes Endowed Chair Precision Oncology
Medical College of Wisconsin Cancer Center
July 17, 2023
“How to make the best of both worlds: Glioblastoma patient-derived organoids and orthotopic xenografts for preclinical studies.”
Anna Golebiewska, PhD
Group Leader, NORLUX Neuro-Oncology Laboratory
Luxembourg Institute of Health
Department of Cancer Research
June 26, 2023
“Progress in Treating KRAS Cancers”
Frank McCormick, PhD, FRS, DSC (HON)
David A. Wood Distinguished Professor of Tumor Biology and Cancer Research
USCF Helen Diller Family Comprehensive Cancer Center Scientific Director, NCI RAS Initiative, Frederick National Laboratory for Cancer Research
May 22, 2023
“Unraveling the Complexity of the Pituitary Neuroendocrine Tumor Microenvironment and the Therapeutic Implications”
Yana Zavros, PhD
Department of Cellular and Molecular Medicine
University of Arizona, College of Medicine Tucson
May 15, 2023
“What is wrong with the drug development paradigm for glioblastoma?”
Mustafa Khasraw, MD
Deputy Director of the Duke Center for Cancer Immunotherapy
Director of Translation and Developmental Therapeutics at the Duke Center for Brain Metastasis
Neuro-oncologist at The Preston Robert Tisch Brain Tumor Center, Duke University
May 08, 2023
“CNS metastases – past, present and future.”
Fernando Santos Pinheiro, MD
Assistant Professor
Associate Program Director of Residency
Department of Neurology
April 17, 2023
“Evolutionary Dynamics and Cancer Treatment”
Solmaz Sahebjam, MD
Associate Research Physician, Neuro-Oncology Branch
Center for Cancer Research, National Cancer Institute
April 3, 2023
“A patient-derived glioblastoma organoid model for testing personized treatment strategies”
Hongjun Song, PhD
Perelman Professor of Neuroscience
Perelman School of Medicine, University of Pennsylvania
January 9, 2023
“The monogenic and polygenic architecture of glioma predisposition: Implications for therapy”
Kyle M. Walsh, MD
Associate Professor, Department of Neurosurgery
Director, Division of Neuro-epidemiology
Co-leader, DCI Neuro-oncology Research Program
Genes & Biology Program Leader, Children’s Health and Discovery Institute
Duke University Medical Center
March 21, 2022
“Challenging Standard-of-Care Paradigms in Brain Tumors in the Precision Oncology”
Vivek Subbiah, MD
Assoc. Prof, Department of Investigational Cancer Therapeutics
Medical Director, Clinical Center for Targeted Therapy
Executive Medical Director, Medical Oncology Research
The University of Texas MD Anderson Cancer Center, Houston, TX
February 21, 2022
“Next-generation sequencing of cerebrospinal fluid in Primary Central Nervous System (CNS) tumors”
Alexandra Miller, MD, PhD
Assistant Member, Department of Neurology
Memorial Sloan Kettering Cancer Center, New York
February 14, 2022
“Novel diagnostic and therapeutic approaches to glioblastoma”
Michael Weller, Prof. Dr. Med.
Chairman
University Hospital Zurich, Department of Neurology
February 7, 2022
“Targeting clonal heterogeneity in treatment-refractory Glioblastoma with novel and empiric immunotherapies”
Sheila K. Singh, MD, PhD, FRCS, FAANS
Professor of Pediatric Neurosurgery
Professor, Biochemistry and Biomedical Sciences,
Director, McMaster Cancer Research Centre
Tier 1 Canada Research Chair, University Scholar,
Chair, McMaster College of Health Inventors
McMaster University, Hamilton, ON, Canada
January 31, 2022
“Targeting IMPDH to Overcome Glioblastoma Resistance to Radiation and Chemotherapy”
Yoshie Umemura, MD
Assistant Professor, Division of Neuro-Oncology,
Department of Neurology
Co-Director, Michigan Medicine
Multidisciplinary Brain Tumor Clinic
January 24, 2022
“Glioma Stem Cells in Tumor Progression and Therapeutic Resistance”
Jennifer Yu, MD, PhD
Associate Professor
Department of Radiation Oncology
Department of Cancer Biology
Cleveland Clinic
Co-Leader Cancer Stem Cell Working Group
Case Comprehensive Cancer Center
January 10, 2022
“Liquid biopsy for patients with glioma: current landscape and future directions”
Stephen Bagley, MD, MSCE
Assistant Professor of Medicine
Medical Oncology
Hospital of the University of Pennsylvania
December 13, 2021
“GBM, PD1, IDO, and IL12”
Rimas V. Lukas, MD
Associate Professor
Associate Chief, Neuro-Oncology Division
Malnati Brain Tumor Institute
Northwestern University
November 29, 2021
“Understanding and targeting hypermutated brain cancer with CRISPR”
Christof Fellmann, PhD
Research Investigator, Gladstone Institutes
Assistant Adjunct Professor, Department of Cellular and Molecular Pharmacology,
University of California, San Francisco
November 8, 2021
“Targeting Stemness in Glioblastoma”
Peter Dirks, MD, PhD, FRCSC
Chief, Division of Neurosurgery
Harold Hoffman/Shoppers Drug Mart Chair in Pediatric Neurosurgery
Senior Scientist, Program in Developmental and Stem Cell Biology
The Hospital for Sick Children, Toronto, Canada
October 11, 2021
“Malignant networks in the brain: a new view on brain tumors”
Frank Winkler, MD
Head of the Experimental Neurooncology Research Group, DKFZ & Managing Senior Physician, Department of Neurology, University Hospital Heidelberg, Germany
October 4, 2021
“Targeting the DDR beyond PARP inhibitors: Novel Agents and Rational Combinations”
Timothy A. Yap, MBBS, PhD, FRCP
Associate Professor, Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine
Medical Director, The Institute for Applied Cancer Science
Associate Director of Translational Research, Khalifa Institute for Personalized Cancer Therapy
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center, Houston, TX
September 13, 2021
“Data-driven computational modeling for the rational design of combination therapy for cancer”
Matthew Lazzara, PhD
Associate Professor
University of Virginia
August 30, 2021
“Killing Brain Tumor Stems Cells”
Jeremy N. Rich, MD, MHS, MBA
Deputy Director for Research, UPMC Hillman Cancer Center Pittsburgh Foundation Chair in Personalized Cancer Therapies Professor, Department of Neurology
August 9, 2021
“Spherical Nucleic Acids for the Precision Treatment of Glioblastoma”
Priya Kumthecar, MD
Associate Professor of Neurology and Hematology/Oncology
Alexander Stegh, PhD
Associate Professor of Neurology and Medicine
February 22, 2021
“Development of Radiation Sensitizers for GBM”
Kevin Camphausen, M.D.
Chief, Radiation Oncology Branch, NCI
February 8, 2021
“The ALT mechanism as a therapeutic target in IDH-mutant lower-grade glioma”
Russell O. Pieper, PhD
Professor and Vice-Chair, UCSF Department of Neurological Surgery
Director of Basic Science, UCSF Brain Tumor Center
January 25, 2021
“Oncolytic Measles Based Immunovirotherapy against GBM: from the Bench to the Clinic”
Evanthia Galanis, MD
Professor of Oncology and Sandra J. Schulze Professor of Novel Therapeutics
Executive Dean for Development
Mayo Clinic
December 7, 2020
“Targeting Pathway Vulnerabilities in Glioma”
Monika E. Hegi, PhD
Head of the Laboratory of Brain Tumour Biology and Genetics
The University of Lausanne
November 16, 2020
“Factors influencing drug transport at the BBB: A critical determinant of efficacy in brain tumors”
William F. Elmquist PharmD, PhD
Distinguished Professor
Department of Pharmaceutics
University of Minnesota
October 26, 2020
“The Post-transcriptional Regulator, HuR as a Novel Therapeutic Target in Malignant Glioma”
L. Burt Nabors, MD
Professor and Director
Division Neuro-oncology/Department of Neurology
The University of Alabama at Birmingham
October 19, 2020
“Pre-clinical and clinical evaluation of radiotherapy-drug combinations for glioblastoma, focusing on the DNA damage response and drug delivery to the tumour margin”
Professor Anthony Chalmers
Chair of Clinical Oncology, University of Glasgow
October 5, 2020
“Glioblastoma as Aberrant Development and Regeneration”
Peter Dirks, MD, PhD, FRCSC
Chief, Division of Neurosurgery
Harold Hoffman/Shoppers Drug Mart Chair in Pediatric Neurosurgery
Senior Scientist, Program in Developmental and Stem Cell Biology
The Hospital for Sick Children, Toronto, Canada
September 28, 2020
“Pragmatic Assessment of Intratumoral Drug Concentrations: Best Intentions and Real Life”
Jaishri Blakeley, MD
Professor of Neurology, Neurosurgery and Oncology
The Marjorie Bloomberg Tiven Professor of Neurofibromatosis
Johns Hopkins University School of Medicine
Director, the Neurofibromatosis Therapeutic Acceleration Program
Director, the Johns Hopkins Comprehensive Neurofibromatosis Program
Director, the Johns Hopkins UCNS Neuro-Oncology Fellowship
August 20, 2020
“Strategies for the Next Generation of Immunotherapies for GBM”
Michael Lim, MD
Professor of Neurosurgery, Oncology, Radiation Oncology
Otolaryngology, and Institute of NanoBiotechnology
Director of the Brain Tumor Immunotherapy Program
Director of the Metastatic Brain Tumor Center
Johns Hopkins University School of Medicine
August 13, 2020
“Genomic evolution of CNS metastases: implications for precision medicine”
Priscilla Brastianos, MD
Director, Central Nervous System Metastasis Center
Stephen E. & Catherine Pappas Center for Neuro-Oncology
July 29, 2020
“Radiosensitizing Glioma Through Disruption of PTEN Nuclear Function”
Frank Furnari, PhD
Member and Head
Laboratory of Tumor Biology
Ludwig Institute for Cancer Research
Professor-Department of Pathology
University of California-San Diego
July 15, 2020
“Dissecting the ecosystem of human gliomas by single-cell genomics”
Mario Suva, MD, PhD
Assistant Professor of Pathology, Harvard Medical School Assistant Molecular Pathologist, Massachusetts General Hospital Institute Member, the Broad Institute of MIT and Harvard